Investors Get the Numbers as Hengrui Rises, Pop Mart Falls

Jiangsu Hengrui Pharmaceuticals reported third-quarter net profit of 2.46 billion yuan, up 88.92 per cent year on year, while Pop Mart reported a 45 to 50 per cent revenue decline. The figures came through company filings and a business update: corporate power gets counted in billions, while the available account says nothing about workers, communities or any response from them.

The Corporate Scoreboard

Hengrui’s revenue reached 8.95 billion yuan (US$1.34 billion), a 20.55 per cent increase and above analyst estimates of 8.55 billion yuan. Its net profit for the three months ended September 30 also exceeded the Bloomberg analyst consensus estimate of 2.38 billion yuan. Investors and analysts had estimates to compare with the company’s results; the filing offered the figures that move that corporate scoreboard.

The company said in a Tuesday filing that stronger sales of innovative drugs and out-licensing revenue contributed to growth. Those are the reasons Hengrui gave. The figures describe the company’s performance, not how the proceeds are distributed or what the increase means for people beyond its accounts; the report provides no such information.

Pop Mart’s business update told a sharply different story. The Chinese toymaker known for its Labubu collectible dolls reported a 45 to 50 per cent year-on-year decline in third-quarter revenue as sales weakened across major markets. Overseas operations and online channels bore the brunt of the slowdown. The company filed the update with the Hong Kong stock exchange late Tuesday.

Where the Decline Landed

Mainland China revenue fell 25 to 30 per cent from a year earlier. In Asia-Pacific markets outside mainland China and Oceania, revenue dropped 65 to 70 per cent. The Americas recorded a 70 to 75 per cent decline, while Europe and other regions saw a 50 to 55 per cent fall. The percentages mark the scale of the reported reversal across Pop Mart’s markets; they don’t identify which workers, sellers or customers absorbed its effects.

Investors have questioned the long-term demand for the collectible dolls. That concern sits alongside the company’s figures, with investors scrutinizing whether sales can hold while Pop Mart’s update records steep falls across regions and channels. The source gives no further detail about those questions or what the company may do in response.

What the Filings Leave Out

There’s no grassroots organizing, mutual aid or direct action described in these reports. There’s also no worker or community account, and no mention of an election, legislative proposal or public program. The information on offer comes from corporate reporting: Hengrui’s Tuesday filing and Pop Mart’s business update to the Hong Kong stock exchange. No nonprofit or institutional helper appears in the account.

The contrast is stark in the figures. Hengrui reported higher revenue and profit, attributing growth to innovative drug sales and out-licensing revenue. Pop Mart reported falling revenue across mainland China, overseas regions and online channels, while investors questioned long-term demand. These numbers tell readers how the companies describe their performance and what investors are watching. They don’t tell readers how corporate decisions were made, who benefits from Hengrui’s growth, or who bears Pop Mart’s slowdown. The filings make the financial results visible. The people outside the figures remain unaccounted for.